REFERENCES
- Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–1043.
- Lapidot T, Sirard C, Vormoor J, A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–648.
- Wang JC, Lapidot T, Cashman JD, High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2406–2414.
- Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–4807.
- Castor A, Nilsson L, strand-Grundstrom I, Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med. 2005;11:630–637.
- Hong D, Gupta R, Ancliff P, Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319:336–339.
- le VC, Hotfilder M, Bomken S, In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008;14: 47–58.
- Kong Y, Yoshida S, Saito Y, CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia. 2008;22: 1207–1213.
- Storms RW, Trujillo AP, Springer JB, Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA. 1999;96:9118–9123.
- Pearce DJ, Taussig D, Simpson C, Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells. 2005;23:752–760.
- Cheung AM, Wan TS, Leung JC, Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia. 2007;21:1423–1430.
- Ran D, Schubert M, Taubert I, Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance. Exp Hematol. 2012;40:155–165.
- Gerber JM, Smith BD, Ngwang B, A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012;119:3571–3577.
- Lin TL, Wang QH, Brown P, Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One. 2010;5:e15262.
- de Figueiredo-Pontes LL, Pintao MC, Oliveira LC, Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom. 2008;74:163–168.
- Misaghian N, Ligresti G, Steelman LS, Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 2009;23:25–42.
- Ebinger M, Witte KE, Ahlers J, High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leuk Res. 2010;34: 1139–1142.
- Chung NG, Buxhofer-Ausch V, Radich JP. The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens. 2006;68:371–385.
- Flohr T, Schrauder A, Cazzaniga G, Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22:771–782.
- van Dongen JJ, Seriu T, Panzer-Grumayer ER, Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731–1738.
- Campana D. Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol. 2008;143:481–489.
- Ran D, Schubert M, Pietsch L, Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol. 2009;37:1423–1434.
- Pei S, Jordan CT. How close are we to targeting the leukemia stem cell? Best Pract Res Clin Haematol. 2012;25:415–418.